Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing tetrahydrofolate needed for DNA and RNA synthesis. This inhibition curtails cell division, particularly affecting fast‑growing immune cells in autoimmune disease and cancer cells in hematologic malignancies.

The specific dose of Metoject is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and treatment goals. Dosing regimens vary widely across the different approved indications.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also excreted in breast milk, so breastfeeding is not recommended while receiving the drug.

To request Metoject, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with other antimetabolites such as azathioprine or cytarabine, methotrexate has a broader range of approved indications, including both autoimmune disorders and several cancers. Its dosing flexibility (intramuscular, intravenous, subcutaneous) and well‑characterized safety profile make it a frequently chosen option, though monitoring requirements are similar across the class.

Metoject should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Metoject is supplied as a sterile solution for injection and can be given intramuscularly, intravenously or subcutaneously by a qualified healthcare professional. The route and rate of administration are selected by the prescriber according to the specific indication and patient factors.

The most serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to bone‑marrow suppression, renal failure, and rare anaphylactic reactions. Patients should be monitored regularly for liver enzymes, lung function, renal parameters and complete blood counts.

Metoject is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, patients with known hypersensitivity to methotrexate or any excipients, and those receiving live vaccines. Caution is also advised for patients with pre‑existing blood disorders or uncontrolled infections.